Trials / Completed
CompletedNCT01715428
Liraglutide and Cardio-Metabolic Risk Markers
Effects of Liraglutide on Cardio-Metabolic Risk Markers
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- University of Palermo · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Incretin-based therapies have shown significant effects beyond those on glucose metabolism. We aim in the present study to evaluate the effects of liraglutide on several cardio-metabolic risk markers.
Detailed description
In details, we will evaluate the effects of liraglutide on carotid-intima media thickness, oxidative stress, ghrelin, heat shock proteins and lipoproteins.
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2012-10-29
- Last updated
- 2017-11-22
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01715428. Inclusion in this directory is not an endorsement.